ClinicalTrials.gov
ClinicalTrials.gov Menu

Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03458897
Recruitment Status : Recruiting
First Posted : March 8, 2018
Last Update Posted : May 4, 2018
Sponsor:
Information provided by (Responsible Party):
Ghada Abusin, University of Michigan

Brief Summary:
The primary purpose of this research is to determine if it is feasible to perform serial magnetic resonance imaging (MRI) to evaluate the amount of bone marrow cells (also called cellularity) and iron stores before and after bone marrow transplantation for severe sickle cell disease.

Condition or disease Intervention/treatment Phase
Sickle Cell Disease Diagnostic Test: serial functional magnetic resonance imaging (MRI) Not Applicable

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Quantitative MRI for Patients With Sickle Cell Disease Undergoing Hematopoietic Cell Transplant
Actual Study Start Date : May 3, 2018
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2023


Arm Intervention/treatment
Experimental: MRI arm
Subjects with sickle cell disease undergoing bone marrow transplantation will undergo serial functional MRI (up to 4 scans).
Diagnostic Test: serial functional magnetic resonance imaging (MRI)
All subjects with sickle cell disease undergoing bone marrow transplantation will undergo up to 4 functional MRI scans.




Primary Outcome Measures :
  1. Feasibility [ Time Frame: 110 days post transplant ]
    Feasibility will be measured by the number of subjects who undergo at least 2 of 4 scheduled functional MRI's


Secondary Outcome Measures :
  1. MRI and hemoglobin S. [ Time Frame: 1 year post transplant ]
    Correlation between functional MRI result and hemoglobin S level.

  2. MRI and neutrophil engraftment [ Time Frame: 1 year post transplant ]
    Correlation between functional MRI result and time to neutrophil engraftment

  3. MRI and chimerism [ Time Frame: 1 year post transplant ]
    Correlation between functional MRI result and time to donor/ recipient chimerism



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   5 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 5 years.
  • Diagnosis of SCD ([Hemoglobin SS (Hb-SS), Hemoglobin SC (Hb-SC) or Hemoglobin S-Beta thalassemia (Hb-Sβ) genotype].
  • Patient is a candidate for an allogeneic HCT.
  • Subject or guardians have given informed consent.

Exclusion Criteria

  • The need for general anesthesia for MRI.
  • Subjects with implanted magnetic devices (e.g. pacemakers) that may malfunction or move in the strong magnetic field.
  • A subject who is pregnant.
  • Previous HCT.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03458897


Contacts
Contact: Connie Varner 7347643140 convarne@med.umich.edu

Locations
United States, Michigan
University of Michigan Recruiting
Ann Arbor, Michigan, United States, 48109
Contact: Connie Varner       convarne@med.umich.edu   
Contact    7347643140      
Principal Investigator: Ghada Abusin, MBBS         
Sponsors and Collaborators
University of Michigan
Investigators
Principal Investigator: Ghada Abusin, MBBS MS University of Michigan

Responsible Party: Ghada Abusin, Assistant Professor, University of Michigan
ClinicalTrials.gov Identifier: NCT03458897     History of Changes
Other Study ID Numbers: HUM00132776
First Posted: March 8, 2018    Key Record Dates
Last Update Posted: May 4, 2018
Last Verified: May 2018

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Ghada Abusin, University of Michigan:
bone marrow cellularity
bone marrow transplant

Additional relevant MeSH terms:
Anemia, Sickle Cell
Anemia, Hemolytic, Congenital
Anemia, Hemolytic
Anemia
Hematologic Diseases
Hemoglobinopathies
Genetic Diseases, Inborn